Delveinsight

FEBRUARY 9, 2021

Deerfield and Dana-Farber Establish Links in USD 130 Million Cancer Research Deal. Deerfield Management has entered into a research agreement with Dana-Farber Cancer Institute to fuel the development of therapeutics and diagnostics for cancer. The funding will help to create and launch Riverway Discoveries.

FDA Approval 52

FDA Approval Marketing Research Protein 52

pharmaphorum

JUNE 12, 2022

Cases of cancer associated with insertional mutagenesis, caused when the viral vectors used to deliver the gene therapy to host cells, have been seen with bluebird’s gene therapies but have been more apparent in trials involving its CALD and sickle cell disease candidates than beti-cel.

Gene Therapy 57

Gene Therapy Gene Marketing Trials 57

pharmaphorum

JANUARY 21, 2022

Flawed funding model. It has become clear that the medicines of the 20 th century, the so-called blockbuster era, are gradually being replaced by drugs designed for smaller groups, specific indication, and even for individual patients,” said Jo De C**k, CEO of Belgium’s National Institute for Health and Disability Insurance.

Medicine 52

Medicine Marketing Manufacturing Production 52

XTalks

DECEMBER 21, 2022

This included greater adoption and acceptance of decentralized clinical trial models, emphasis on patient-centric approaches in trials, growing digitization of healthcare and dealing with drug manufacturing challenges. Here are some of the top life science trends and topics from 2022. Gene Therapy Approvals. million for a single infusion.

Life Science 52

Life Science Gene Therapy Gene Clinical Trials 52

The Pharma Data

MAY 5, 2021

Lilly hit by staff accusations, FDA scrutiny at COVID drug factories ( Reuters ). Pharma showers Menendez with rare, off-cycle burst of campaign cash as Democrats eye drug pricing reforms ( STAT ). Rising wholesale drug prices really do matter to half of all commercially insured Americans ( STAT ).

Vaccination 52

Vaccination Vaccine Gene Therapy Contract Packaging 52

The Pharma Data

MAY 4, 2021

up 28%, primarily driven by continued strong demand in the metastatic and non-metastatic castration-resistant prostate cancer indications, as well as the metastatic castration-sensitive prostate cancer indication, which was approved in the U.S. in December 2019; and. If approved, TicoVac would be the first vaccine in the U.S.

Vaccination 40

Vaccination Vaccine Production Sales 40